Startup
Advancing a therapy for treating inflammatory bowel disease.
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Micromune Therapeutics raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator | - |
Companies Micromune Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Micromune Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Eight Australian health startups received equity-free grants totaling 18.5 million dollars from the CUREator+ program, supported by government funding and delivered with partners Brandon BioCatalyst and ANDHealth.
Biotech incubator CUREator's second round distributes $12 million among 19 health-focused startups, supported by government funding, while a new MedTech program backed by $50 million arrives later in the year.
CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.